The channel is part
of the risk
The same molecule can be an approved medicine in one channel and an unapproved research chemical in another. We track the status by region and we link the regulator.
The FDA reviewed seven peptides on 23–24 July 2026 — BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax and Epitalon. Read what the FDA reviewed and what each outcome means.
The FDA approves semaglutide as a prescription medicine. The FDA declared the shortage resolved on 21 February 2025. Enforcement discretion for 503A pharmacies ended on 22 April 2025 and for 503B facilities on 22 May 2025. On 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List.
FDA →Verified Jul 23, 2026
The FDA approves tesamorelin for one clinical indication. Any other use falls outside the approval.
FDA →Verified Jul 23, 2026
The FDA placed BPC-157 in Category 2 in 2023. A 503A pharmacy cannot compound it. The Pharmacy Compounding Advisory Committee reviewed it on 23 July 2026 for the 503A Bulks List. WADA names BPC-157 under S0 and prohibits it at all times.
FDA, WADA →Verified Jul 23, 2026
No FDA approval. The Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 for wound healing. WADA prohibits it in sport.
FDA, WADA →Verified Jul 23, 2026
No FDA approval. The FDA placed ipamorelin acetate in Category 2. WADA prohibits it in sport.
FDA, WADA →Verified Jul 23, 2026
The EMA authorizes semaglutide as a prescription medicine across the EU.
EMA →Verified Jul 23, 2026
No EMA marketing authorization. Research supply and possession rules vary by member state.
EMA →Verified Jul 23, 2026
The MHRA authorizes no research peptide for human use. Human-use marketing is prohibited. Possession for laboratory research is not itself an offence.
MHRA →Verified Jul 23, 2026
The TGA schedules many peptides. Import is tightly controlled and most have no approval for human use.
TGA →Verified Jul 23, 2026
Each row links its regulator and shows a last-verified date. Regulatory status changes by jurisdiction and by month. Confirm current status with the regulator's own page and a qualified professional.
Access · the honest framing
“For research use only” is a legal boundary, not a quality guarantee.
Two channels, two different risk profiles
The channel you are in matters more than the molecule. Here is what each channel gives you.
The clinical channel gives you
- A prescription from a licensed clinician
- Manufacture under GMP rules
- Dose oversight and adverse-event reports
- Identity checks and a supply record
- Approved indications only
The research channel gives you
- A product sold for laboratory research use only
- No human-use approval and no oversight
- Quality that depends on one vendor
- A legal label, not a quality guarantee
- All of the verification burden
Legitimate routes, in order of oversight
Licensed prescriber
For approved compounds like semaglutide or tesamorelin, a licensed clinician is the only route with real safety oversight.
Regulated clinical trials
Investigational peptides may be accessible through registered trials with informed consent and monitoring.
Research supply (buyer beware)
Research-only vendors exist for laboratory work. Quality is unregulated — this is where our vendor rankings and COA guidance matter most.